Daniel Rauch
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
Moccia A, Rauch D, Vorobiof D, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Raats J, Del Giglio A, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Zucca E. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Adv 2020; 4:5951-5957.
Dec 8, 2020Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
Dec 8, 2020Blood Adv 2020; 4:5951-5957
Moccia Alden A, Rauch Daniel, Vorobiof Daniel A, Lohri Andreas, Ruegsegger Céline, Biaggi Rudolf Christine, Rusterholz Corinne, Hayoz Stefanie, Ghielmini Michele, Raats Johann, Del Giglio Auro, Taverna Christian, Schär Sämi, Vanazzi Anna, Rondeau Stephanie, Hitz Felicitas, Mingrone Walter, Pabst Thomas, Cevreska Lidija, Zucca Emanuele
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Benz R, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Feller A, Rauch D, Blum S, Mey U, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Stussi G. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv 2020; 4:3699-3707.
Aug 11, 2020Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Aug 11, 2020Blood Adv 2020; 4:3699-3707
Benz Rudolf, O'Meara Stern Alix, Cantoni Nathan, Bargetzi Mario, Bianchi-Papina Elena, Rossi Davide, Passweg Jakob, Lohri Andreas, Berardi Simona, Feller Anita, Rauch Daniel, Blum Sabine, Mey Ulrich, Arn Kornelius, Andres Martin, Pabst Thomas, Baumann Michael, Novak Urban, Hitz Felicitas, Hess Urs, Zenhaeusern Reinhard, Chalandon Yves, Stussi Georg
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Zucca E, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei S, Ghielmini M, Kimby E, Novak U, Lohri A, Ferreri A, Rondeau S, Vanazzi A, Østenstad B, Mey U, Rauch D, Wahlin B, Hitz F, Hernberg M, Johansson A, de Nully Brown P, Hagberg H, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood 2019; 134:353-362.
May 17, 2019Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
May 17, 2019Blood 2019; 134:353-362
Zucca Emanuele, Zander Thilo, Bersvendsen Hanne, Bargetzi Mario, Mingrone Walter, Krasniqi Fatime, Dirnhofer Stefan, Hayoz Stefanie, Hawle Hanne, Vilei Simona Berardi, Ghielmini Michele, Kimby Eva, Novak Urban, Lohri Andreas, Ferreri Andrés J M, Rondeau Stephanie, Vanazzi Anna, Østenstad Bjørn, Mey Ulrich J M, Rauch Daniel, Wahlin Björn E, Hitz Felicitas, Hernberg Micaela, Johansson Ann-Sofie, de Nully Brown Peter, Hagberg Hans, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). Eur J Cancer 2017; 89:82-89.
Dec 11, 2017Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
Dec 11, 2017Eur J Cancer 2017; 89:82-89
von Moos Roger, Plasswilm Ludwig, Zwahlen Daniel, Meier Urs R, Yan Pu, Izzo Paola, Klingbiel Dirk, Bärtschi Daniela, Zaugg Kathrin, Saletti Piercarlo, Rauch Daniel, Koeberle Dieter, Schacher Sabina, Hayoz Stefanie, Winterhalder Ralph C, Roth Arnaud, Bodoky György, Samaras Panagiotis, Berger Martin D, Swiss Group for Clinical Cancer Research (SAKK)
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell R, Shah R, Porta R, Majem M, Gómez-Codina J, Camps C, Thomas M, Rauch D, Barlesi F, Hanrahan E, Kammler R, Stahel R, Molina-Vila M, Shames D, Tam R, Karachaliou N, Kassapian M, Rabaglio M, Ruepp B, Coate L, Puente J, Aix S, Palmero R, Massutí B, Peters S, Gautschi O, Curioni-Fontecedro A, Felip E, Dafni U, Carcereny E, Früh M, Reguart N, Froesch P, Favaretto A, Bidoli P, Cuffe S, Kotsakis A, Popat S, Pless M, BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017; 5:435-444.
Apr 10, 2017Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Apr 10, 2017Lancet Respir Med 2017; 5:435-444
Rosell Rafael, Shah Riyaz, Porta Rut, Majem Margarita, Gómez-Codina Jose, Camps Carlos, Thomas Michael, Rauch Daniel, Barlesi Fabrice, Hanrahan Emer, Kammler Roswitha, Stahel Rolf A, Molina-Vila Miguel A, Shames David S, Tam Rachel, Karachaliou Niki, Kassapian Marie, Rabaglio Manuela, Ruepp Barbara, Coate Linda, Puente Javier, Aix Santiago Ponce, Palmero Ramon, Massutí Bartomeu, Peters Solange, Gautschi Oliver, Curioni-Fontecedro Alessandra, Felip Enriqueta, Dafni Urania, Carcereny Enric, Früh Martin, Reguart Noemí, Froesch Patrizia, Favaretto Adolfo, Bidoli Paolo, Cuffe Sinead, Kotsakis Athanasios, Popat Sanjay, Pless Miklos, BELIEF collaborative group
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer 2016
Nov 23, 2016Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Nov 23, 2016Clin Lung Cancer 2016
Gautschi Oliver, Ochsenbein Adrian F, Mach Nicolas, Biaggi Christine, Schneider Martina, Zander Thilo, Froesch Patrizia, Peters Solange, Pless Miklos, Rauch Daniel, Cathomas Richard, Stahel Rolf A, Früh Martin, Betticher Daniel C, Zippelius Alfred, Matter-Walstra Klazien, Li Qiyu, Rothschild Sacha I
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC cancer 2016; 16:780.
Oct 10, 2016SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Oct 10, 2016BMC cancer 2016; 16:780
Rochlitz Christoph, Rordorf Tamara, Rauch Daniel, Müller Andreas, Ruhstaller Thomas, Vetter Marcus, Trojan Andreas, Hasler-Strub Ursula, Cathomas Richard, Winterhalder Ralph, Borner Markus, Bärtschi Daniela, Bigler Martin, von Moos Roger, Bernhard Jürg, Matter-Walstra Klazien, Wicki Andreas, Zaman Khalil, Anchisi Sandro, Küng Marc, Na Kyung-Jae
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)
Cathomas R, Gillessen Sommer S, Manetsch G, Bernhard J, Mohaupt M, Roggero E, Rauch D, Vilei S, Hayoz S, Kenner H, von Burg P, Elliott T, Rothermundt C, Winterhalder R, Mark M, Crabb S, Swiss Group for Clinical Cancer Research SAKK. Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). Prostate 2016; 76:1519-1527.
Jul 25, 2016Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)
Jul 25, 2016Prostate 2016; 76:1519-1527
Cathomas Richard, Gillessen Sommer Silke, Manetsch Gabriela, Bernhard Jürg, Mohaupt Markus G, Roggero Enrico, Rauch Daniel, Vilei Simona Berardi, Hayoz Stefanie, Kenner Heike, von Burg Philippe, Elliott Tony, Rothermundt Christian, Winterhalder Ralph, Mark Michael, Crabb Simon J, Swiss Group for Clinical Cancer Research SAKK
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Colleoni M, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber R, Regan M, Coates A, Price K, Viale G, Kralidis E, Tondini C, Gray K, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E, Gomez H, Linderholm B, Puglisi F, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol 2016
Jun 20, 2016Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Jun 20, 2016J Clin Oncol 2016
Colleoni Marco, Eniu Alexandru, Cagossi Katia, Rauch Daniel, Chirgwin Jacquie, Gelber Richard D, Regan Meredith M, Coates Alan S, Price Karen N, Viale Giuseppe, Kralidis Elena, Tondini Carlo, Gray Kathryn P, Gelber Shari, Láng István, Thürlimann Beat, Gianni Lorenzo, Abdi Ehtesham A, Gomez Henry L, Linderholm Barbro K, Puglisi Fabio, Goldhirsch Aron
Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis
Elicin O, Giger R, Ghadjar P, Geretschlager A, Plasswilm L, Ambarcioglu P, Rauch D, Bromme J, Schmücking M, Aebersold D. Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis. J BUON 2016; 21:175-81.
Jan 1, 2016Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis
Jan 1, 2016J BUON 2016; 21:175-81
Elicin Olgun, Giger Roland, Ghadjar Pirus, Geretschlager Andreas, Plasswilm Ludwig, Ambarcioglu Pinar, Rauch Daniel, Bromme Jens, Schmücking Michael, Aebersold Daniel M
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
Taverna C, Zucca E, Heijnen I, Rusterholz C, Rondeau S, Biaggi Rudolf C, Lohri A, Vorobiof D, Rauch D, Raats J, Laszlo D, Vanazzi A, Del Giglio A, Cevreska L, Pabst T, Mingrone W, Hitz F, Martinelli G, Ghielmini M. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. J Clin Oncol 2015; 34:495-500.
Dec 28, 2015Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
Dec 28, 2015J Clin Oncol 2015; 34:495-500
Taverna Christian, Zucca Emanuele, Heijnen Ingmar A F M, Rusterholz Corinne, Rondeau Stephanie, Biaggi Rudolf Christine, Lohri Andreas, Vorobiof Daniel A, Rauch Daniel, Raats Johann, Laszlo Daniele, Vanazzi Anna, Del Giglio Auro, Cevreska Lidija, Pabst Thomas, Mingrone Walter, Hitz Felicitas, Martinelli Giovanni, Ghielmini Michele
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Pless M, Bijelovic M, Ochsenbein A, Meier U, Mamot C, Rauch D, Gautschi O, Betticher D, Mirimanoff R, Peters S, Roth A, Zippelius A, Stupp R, Ris H, Stahel R, Weder W, Thierstein S, Gerard M, Xyrafas A, Früh M, Cathomas R. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386:1049-56.
Aug 11, 2015Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Aug 11, 2015Lancet 2015; 386:1049-56
Pless Miklos, Bijelovic Milorad, Ochsenbein Adrian, Meier Urs R, Mamot Christoph, Rauch Daniel, Gautschi Oliver, Betticher Daniel C, Mirimanoff René-Olivier, Peters Solange, Roth Arnaud, Zippelius Alfred, Stupp Roger, Ris Hans-Beat, Stahel Rolf A, Weder Walter, Thierstein Sandra, Gerard Marie-Aline, Xyrafas Alexandros, Früh Martin, Cathomas Richard
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
Mar 5, 2015Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Mar 5, 2015Clin Lung Cancer 2015; 16:358-65
Gautschi Oliver, Savic Spasenija, Jaggi Rolf, Leibundgut Elisabeth Oppliger, Largiadèr Carlo, Brutsche Martin, Pilop Christiane, Stalder Lukas, Pless Miklos, Ochsenbein Adrian F, Bubendorf Lukas, Feilchenfeldt Jonas, Rauch Daniel, Mach Nicholas, Rothschild Sacha I, Li Qiyu, Stahel Rolf A, Zippelius Alfred, Cathomas Richard, Früh Martin, Betticher Daniel C, Peters Solange, Swiss Group for Clinical Cancer Research
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PloS one 2013; 8:e72966.
Sep 10, 2013EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Sep 10, 2013PloS one 2013; 8:e72966
Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Crowe Susanne, Bubendorf Lukas, Gautschi Oliver, Rauch Daniel, Cathomas Richard, Dröge Cornelia, Betticher Daniel, Früh Martin, Rothschild Sacha, Swiss Group for Clinical Cancer Research
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)
Früh M, Pless M, Fustier P, Küttel E, Simcock M, Rauch D, Krasniqi F, Erdmann A, Mamot C, Zippelius A, Tscherry G, Siano M, Cathomas R, Swiss Group for Clinical Cancer Research. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer 2012; 14:34-9.
May 24, 2012Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)
May 24, 2012Clin Lung Cancer 2012; 14:34-9
Früh Martin, Pless Miklos, Fustier Pierre, Küttel Erika, Simcock Mathew, Rauch Daniel, Krasniqi Fatima, Erdmann Andreas, Mamot Christoph, Zippelius Alfred, Tscherry Gregor, Siano Marco, Cathomas Richard, Swiss Group for Clinical Cancer Research
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011; 29:626-31.
Jan 4, 2011Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Jan 4, 2011J Clin Oncol 2011; 29:626-31
Ruhstaller Thomas, Brauchli Peter, Inauen Roman, Widmer Lucas, Mingrone Walter, Gautschi Oliver, Rauch Daniel, Schneider Paul M, Montemurro Michael, Moosmann Peter, von Moos Roger, Kranzbuehler Helmut, Dietrich Daniel, Pless Miklos, Hess Viviane